- OralNilotinibTasignaBinds both active & inactive conformation of Bcr-Abl kinase, resulting in reduced resistance
- Mechanism of Action
- Inhibits the Bcr-Abl tyrosine kinase as well as the stem cell receptor factor (cKIT) and several other receptor tyrosine kinases.
- Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase or with resistance or intolerance to imatinib
- Adverse Effects